Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) rose 5.4% during mid-day trading on Wednesday . The stock traded as high as $11.66 and last traded at $11.71. Approximately 835,363 shares traded hands during trading, a decline of 85% from the average daily volume of 5,597,161 shares. The stock had previously closed at $11.11.
Analysts Set New Price Targets
ROIV has been the subject of several analyst reports. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday.
View Our Latest Analysis on ROIV
Roivant Sciences Price Performance
The company has a market capitalization of $7.78 billion, a price-to-earnings ratio of -45.80 and a beta of 1.16. The company's 50-day moving average price is $10.97 and its two-hundred day moving average price is $10.94.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. The business had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. During the same period last year, the business posted ($0.23) earnings per share. On average, equities research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Insider Transactions at Roivant Sciences
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the completion of the sale, the chief operating officer now owns 1,116,345 shares of the company's stock, valued at $11,409,045.90. The trade was a 8.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,656,667 shares of company stock valued at $29,570,112. Corporate insiders own 7.90% of the company's stock.
Institutional Investors Weigh In On Roivant Sciences
A number of large investors have recently bought and sold shares of ROIV. Parallel Advisors LLC grew its holdings in Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock worth $25,000 after purchasing an additional 1,108 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Roivant Sciences during the fourth quarter valued at about $39,000. UMB Bank n.a. increased its position in shares of Roivant Sciences by 112.7% during the first quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock worth $42,000 after acquiring an additional 2,195 shares in the last quarter. Finally, Fifth Third Bancorp increased its position in shares of Roivant Sciences by 59.3% during the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock worth $52,000 after acquiring an additional 1,905 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.